 |
0 Diseases |  |
12 Trials |
|
12 Trials |  |
153 News |  |
| «1234 |
- linrodostat (BMS-986205) / BMS, Ono Pharma
New P1 trial: A Study to Evaluate the Bioavailability of BMS-986205 (clinicaltrials.gov) - Dec 14, 2017
P1, N=8, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | linrodostat (BMS-986205) / BMS, Ono Pharma
New P1 trial: A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet (clinicaltrials.gov) - Dec 5, 2017
P1, N=40, Recruiting, Sponsor: Bristol-Myers Squibb
- ||| linrodostat (BMS-986205) / BMS, Ono Pharma
New P1 trial: A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects (clinicaltrials.gov) - Nov 17, 2017
P1, N=56, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | Biomarker, New P1 trial, PD(L)-1 Biomarker, IO biomarker: ADVISE: An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (clinicaltrials.gov) - Nov 7, 2017
P1, N=50, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- |||||||||| linrodostat (BMS-986205) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS
New P3 trial, PD(L)-1 Biomarker: An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma (clinicaltrials.gov) - Nov 6, 2017
P3, N=700, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- linrodostat (BMS-986205) / BMS, Ono Pharma
Trial completion: Pharmacokinetics and Metabolism Study in Healthy Male Participants (clinicaltrials.gov) - Nov 6, 2017
P1, N=9, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed
- | linrodostat (BMS-986205) / BMS, Ono Pharma
New P1 trial: An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants (clinicaltrials.gov) - Oct 17, 2017
P1, N=32, Recruiting, Sponsor: Bristol-Myers Squibb
- linrodostat (BMS-986205) / BMS, Ono Pharma
New P1 trial: Pharmacokinetics and Metabolism Study in Healthy Male Participants (clinicaltrials.gov) - Aug 11, 2017
P1, N=9, Recruiting, Sponsor: Bristol-Myers Squibb
- linrodostat (BMS-986205) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS
Enrollment open, PD(L)-1 Biomarker: A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors (clinicaltrials.gov) - Aug 1, 2017
P1, N=18, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Enrollment change: FRACTION-RCC: A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jul 2, 2017
P2, N=200, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting N=650 --> 200
- | linrodostat (BMS-986205) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS
New P1 trial, PD(L)-1 Biomarker: A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors (clinicaltrials.gov) - Jun 20, 2017
P1, N=18, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||| Enrollment change: FRACTION-GC: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (clinicaltrials.gov) - Jun 1, 2017
P2, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
N=650 --> 200 N=910 --> 300
- ||| linrodostat (BMS-986205) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date: An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - May 30, 2017
P1/2, N=907, Recruiting, Sponsor: Bristol-Myers Squibb
N=910 --> 300 N=252 --> 907 | Trial primary completion date: Dec 2018 --> Apr 2019 | N=252 --> 907 | Trial primary completion date: Dec 2018 --> Apr 2019
- |||| Enrollment open: FRACTION-RCC: A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Feb 8, 2017
P2, N=650, Recruiting, Sponsor: Bristol-Myers Squibb
N=252 --> 907 | Trial primary completion date: Dec 2018 --> Apr 2019 | N=252 --> 907 | Trial primary completion date: Dec 2018 --> Apr 2019 Not yet recruiting --> Recruiting
- ||||| New P2 trial: FRACTION-RCC: A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Dec 19, 2016
P2, N=650, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- |||| Enrollment open: FRACTION-GC: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (clinicaltrials.gov) - Dec 1, 2016
P2, N=910, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| New P2 trial: FRACTION-GC: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (clinicaltrials.gov) - Oct 16, 2016
P2, N=910, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || Trial primary completion date: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 9, 2016
P2, N=504, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2020 --> Apr 2021
- ||| Enrollment change: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 13, 2016
P2, N=504, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Apr 2020 --> Apr 2021 N=685 --> 504
- |||| Enrollment open: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 22, 2016
P2, N=685, Recruiting, Sponsor: Bristol-Myers Squibb
N=685 --> 504 Not yet recruiting --> Recruiting
- ||||| New P2 trial: FRACTION-Lung: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 25, 2016
P2, N=685, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- |||| linrodostat (BMS-986205) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Feb 26, 2016
P1/2, N=252, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| linrodostat (BMS-986205) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial: An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Jan 20, 2016
P1/2, N=252, Not yet recruiting, Sponsor: Bristol-Myers Squibb